论文部分内容阅读
晚期食管鳞癌患者35例,应用紫杉醇135～150mg/m2,加入生理盐水500ml,静脉滴注3h;奈达铂80mg/m2,加入生理盐水500ml中静滴,以21d为1周期每周期第1d使用,连用2个周期后评价疗效。结果总有效率54.3%(19/35),完全缓解3例,部分缓解16例,稳定7例。中位缓解时间为4.6个月,中位生存时间9.8月,主要不良反应为骨髓抑制所致的血小板及白细胞减少、骨骼酸痛,消化道反应轻,未发现严重肝肾功能损害。奈达铂联合紫杉醇治疗晚期食管癌近期疗效较好,毒副反应较轻。
Thirty-five patients with advanced esophageal squamous cell carcinoma were treated with paclitaxel 135-150 mg/m2, normal saline 500 ml, intravenous drip for 3 h, nedaplatin 80 mg/m2, intravenously in physiological saline 500 ml, 21 d for 1 cycle, 1 d for each cycle. After use, the curative effect was evaluated after 2 cycles. Results The total effective rate was 54.3% (19/35), complete remission was 3, partial remission was 16 and stability was 7 cases. The median time to remission was 4.6 months, and the median survival time was 9.8 months. The major adverse reactions were platelet and leukopenia due to myelosuppression, bone soreness, and light gastrointestinal reaction. No severe liver and kidney damage was found. Nidaplatin combined with paclitaxel in the treatment of advanced esophageal cancer has good short-term efficacy and mild side effects.